DoubleLine ETF Adviser’s Vertex Pharmaceuticals VRTX Stock Holding History

DoubleLine ETF Adviser’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Sell	2,949 -284	-9%	-$126K	0.6%	58
2026 Q1	$1.44M	Buy	+3,233	New	+$1.51M	0.55%	52

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DoubleLine ETF Adviser's VRTX Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its Vertex Pharmaceuticals (VRTX) stake by 8.8% in Q2 2026, selling an estimated $126K and leaving 2,949 shares worth $1.46M. The position accounts for 0.6% of the portfolio, ranked #58.

DoubleLine ETF Adviser first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

DoubleLine ETF Adviser held 2,949 shares of Vertex Pharmaceuticals worth $1.46M as of Q2 2026.
DoubleLine ETF Adviser sold 284 Vertex Pharmaceuticals shares in Q2 2026, an estimated $126K.
Vertex Pharmaceuticals made up 0.6% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #58 holding.
DoubleLine ETF Adviser first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.